Patents by Inventor Wade E. Bolton

Wade E. Bolton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for distinguishing viable, early apoptotic, late apoptotic, and necrotic cells
    Patent number: 5945291
    Abstract: The present invention provides a method for distinguishing between viable, early apoptotic, late apoptotic and necrotic cells utilizing multi-color immunofluorescence.
    Type: Grant
    Filed: November 10, 1997
    Date of Patent: August 31, 1999
    Assignee: Coulter International Corp.
    Inventors: Wade E. Bolton, Steven K. Koester
  • Method of analyzing tumor cell DNA content through tumor cell enrichment
    Patent number: 5798217
    Abstract: The invention provides a method for enriching a sample in tumor cells and determining the DNA ploidy and proliferative index of the tumor cells present in the sample. The method uses a pan-leukocyte monoclonal antibody conjugated to a separable substrate such as magnetic microspheres to conjugate and remove leukocytes from the sample. A fluorescently labelled monoclonal antibody specific to a tumor associated antigen or an antigen arising from the presence of the tumor and a DNA staining reagent are added to the leukocyte depleted sample. The sample is then analyzed by dual color flow cytometry to determine cells having an abnormal DNA content by gating on fluorescently labelled cells.
    Type: Grant
    Filed: June 12, 1995
    Date of Patent: August 25, 1998
    Assignee: Coulter Corporation
    Inventors: Wade E. Bolton, Norma Sue Kenyon, Olavi Siiman, Robert J. Schmittling
  • Anti-CD3 antibody-aminodextran conjugates for induction of T-cell activation and proliferation
    Patent number: 5658741
    Abstract: The invention describes the use of novel aminodextran compounds containing about 5-20% by weight amine groups to bind a plurality of monoclonal antibodies. The resulting antibody-aminodextran compounds may be used to induce the activation and proliferation of selected mammalian cells. Specific examples are given using an anti-CD3 monoclonal antibody conjugated two aminodextrans containing about 5% and 16%, respectively, by weight amine groups as an agent for inducing the activation and proliferation of T cells.
    Type: Grant
    Filed: July 19, 1995
    Date of Patent: August 19, 1997
    Assignee: Coulter Corporation
    Inventors: Wade E. Bolton, John A. Maples, Olavi Siiman, Norma Sue Kenyon, Cynthia G. Healy
  • Anti-CD3 antibody-aminodextran conjugates for induction of T-cell activation and proliferation
    Patent number: 5527713
    Abstract: The invention describes the use of novel aminodextran compounds containing about 5-20% by weight amine groups to bind a plurality of monoclonal antibodies. The resulting antibody-aminodextran compounds may be used to induce the activation and proliferation of selected mammalian cells. Specific examples are given using an anti-CD3 monoclonal antibody conjugated two aminodextrans containing about 5% and 16%, respectively, by weight amine groups as an agent for inducing the activation and proliferation of T cells.
    Type: Grant
    Filed: July 19, 1995
    Date of Patent: June 18, 1996
    Assignee: Coulter Corporation
    Inventors: Wade E. Bolton, John A. Maples, Olavi Siiman, Norma S. Kenyon, Cynthia G. Healy